2022-04-28 Regulatory
ViewReleaseInStandardHtml

NeoDynamics publishes supplementary document introducing listing on Nasdaq First North Growth Market

NeoDynamics AB (publ)  (NeoDynamics or "the Company") received a conditional approval for admission to trading of the Company's shares on the Nasdaq First North Growth Market (“Nasdaq First North”) on April 12, 2022. For this reason, the company has published a Supplementary document on its website in accordance with Nasdaq First North Growth Markets' listing requirements.

 

The Supplementary document can be found on the Company's website:

SV: https://www.neodynamics.com/sv-se/aktien

EN: https://www.neodynamics.com/en-gb/shares

DE: https://www.neodynamics.com/de-de/aktien

The Prospectus published on March 4, 2022 and the  Supplementary Document constitutes the Company Description. The Supplementary document does not constitute a prospectus, has not been approved by the Swedish Financial Supervisory Authority and does not contain an offer to subscribe for the Company's shares or other financial instruments in Sweden or in any other jurisdiction.

 

 

For more information, please contact:
Anna Eriksrud, CEO

Phone:  +46 708 444 966
Email: anna.eriksrud@neodynamics.com
 


About NeoDynamics
NeoDynamics AB (publ) is a Swedish medical technology company that works to improve the diagnosis and treatment of cancer. The company's first product NeoNavia®, which is a new pulse biopsy system for ultrasound-guided tissue sampling, is now being introduced to the market. The biopsy system is based on a patented pulse technology based on research at Karolinska Institutet in Sweden. NeoNavia® is being evaluated for the diagnosis of breast cancer at leading clinics in the UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in the breasts and lymph nodes of over 500 patients.

 

About NeoNavia          

NeoNavia is a modern biopsy system with a completely new patented pulse technology that is intended to be used for ultrasound-guided tissue sampling. It consists of a base unit, a handset and three types of biopsy needles. Each needle type is driven by the new pulse technology that provides a more controlled needle insertion and precise placement of the needle in the tumor while enabling high-quality tissue samples from both breasts and lymph nodes. The pulse biopsy system NeoNavia is designed to offer doctors and patients a precise and reliable tissue sampling that enables a correct diagnosis and individualized treatment.